GlaxoSmithKline’s (NYSE:GSK) fourth quarter earnings were less than stellar as the British drugmaker’s profits were squeezed by legal charges for diabetes drug Avandia and declining sales of its products due to generic competition. …
Recently, GSK stock has done better, largely on the back of its HIV drug business, which the company had considered spinning off in an initial public offering before deciding to retain it. GSK said its board would consider both internal and …
Dear Mr. Berko: My broker has recommended that I invest $20,000 and buy 500 shares of GlaxoSmithKline, a world-class drug company. The dividend is $2.48 and that yields a very attractive 5.9 percent He thinks Glaxo's problems are …
After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and GlaxoSmithKline wasn't one …
Shares of GlaxoSmithKline stock rose 1.3% in Monday trading. --CNN's Terry Frieden and CNN's Medical Unit contributed to this report
Anacor Pharmaceuticals Inc. ANAC said its collaboration partner GlaxoSmithKline PLC GSK, -0.74% has suspended four clinical trials of a potential infection treatment due to a recently identified microbiological finding in a small number …
But the biggest dividend among Big Pharma stocks belongs to GlaxoSmithKline PLC (NYSE:GSK). The Brentford, England-based company’s 5% dividend yield stands well above other health care giants such asJohnson & Johnson …
StockMarketWire.com - Sir Philip Hampton, Chairman, bought 3,423 shares in the company on the 7th February 2018 at a price of 1278.00p. The Director now holds 33,817 shares representing 0.00% of the shares in issue.
On Sept. 24 it announced plans to begin human trials. Its stock was up close to 2 percent at closing. GlaxoSmithKline’s stock rose on the news as well. The pharmaceutical giant came to its Ebola research through the acquisition of a small …